The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The histamine H3 receptor: from discovery to clinical trials with pitolisant
Open accessAbstract
The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. The same in vitro test was used to design, in 1987, the first highly selective and potent H3‐autoreceptor ligands, the antagonist thioperamide and the agonist (R)alphamethylhistamine which enhances and inhibits, respectively, the activity of histaminergic neurons in brain. The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes. In 1990, the cloning of the gene of the H3‐receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3‐receptor inverse agonist programs in many drug companies. Pitolisant (BF2.649, 1‐{3‐[3‐(4‐chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics. Its wake‐promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units. The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder. LINKED ARTICLES: This review is dedicated to the memory of Sir James Black who recently passed away and whose achievements in classical pharmacology and drug design have been examples to the author throughout his career.BJP published an issue in 2010 on Analytical Receptor Pharmacology in Drug Discovery, which was dedicated to the memory of Sir James Black. To view this issue visit http://dx.doi.org/10.1111/bph.2010.161.issue‐6 In 2009 BJP published a Histamine themed issue. To view this issue visit http://dx.doi.org/10.1111/bph.2009.157.issue‐1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“Although this interpretation was challenged, Chemelli et al. (1999) proposed that these episodes correspond to cataplexy episodes in narcoleptic patients, and another H3R antagonist was described to decrease cataplectic episodes in the Doberman ‘narcoleptic’ dog (Bonaventure et al., 2007).”
BackgroundDefinition and Antagonism of Histamine H2-receptors
BLACK, J. W., DUNCAN, W. A. M., DURANT, C. J., GANELLIN, C. R., & PARSONS, E. M. (1972) · Nature · doi:10.1038/236385a0 · Cited by 2,259
Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
Arrang, J.-M., Garbarg, M., & Schwartz, J.-C. (1983) · Nature · doi:10.1038/302832a0 · Cited by 1,575
Self-citationHistamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228
Histaminergic transmission in the mammalian brain
Schwartz, J. C., Arrang, J. M., Garbarg, M., Pollard, H., & Ruat, M. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.1.1 · Cited by 944
Self-citationHighly potent and selective ligands for histamine H3-receptors
Arrang, J.-M., Garbarg, M., Lancelo, J.-C., Lecomte, J.-M., Pollard, H., Robba, M., Schunack, W., & Schwartz, J.-C. (1987) · Nature · doi:10.1038/327117a0 · Cited by 903
Self-citationHistamine-containing neurons in the rat hypothalamus.
Panula, P., Yang, H. Y., & Costa, E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2572 · Cited by 736
Dauvilliers, Y., Arnulf, I., & Mignot, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60237-2 · Cited by 725
Cloning and Functional Expression of the Human Histamine H3Receptor
Lovenberg, T. W., Roland, B. L., Wilson, S. J., Jiang, X., Pyati, J., Huvar, A., Jackson, M. R., & Erlander, M. G. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.6.1101 · Cited by 696
Alternative splicing directs the expression of two D2 dopamine receptor isoforms
Giros, B., Sokoloff, P., Martres, M.-P., Riou, J.-F., Emorine, L. J., & Schwartz, J.-C. (1989) · Nature · doi:10.1038/342923a0 · Cited by 685
Self-citationArousal effect of orexin A depends on activation of the histaminergic system
Huang, Z.-L., Qu, W.-M., Li, W.-D., Mochizuki, T., Eguchi, N., Watanabe, T., Urade, Y., & Hayaishi, O. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181330998 · Cited by 553
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529
High constitutive activity of native H3 receptors regulates histamine neurons in brain
Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, C. R., & Arrang, J.-M. (2000) · Nature · doi:10.1038/35048583 · Cited by 461
Lin, J.-S., Dauvilliers, Y., Arnulf, I., Bastuji, H., Anaclet, C., Parmentier, R., Kocher, L., Yanagisawa, M., Lehert, P., Ligneau, X., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.003 · Cited by 269
Self-citationModulation of neurotransmitter release via histamine H3heteroreceptors
Schlicker, E., Malinowska, B., Kathmann, M., & Göthert, M. (1994) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1994.tb00789.x · Cited by 263
Histaminergic Mechanisms in Brain
Schwartz, J. (1977) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.17.040177.001545 · Cited by 257
Self-citationLigneau, X., Perrin, D., Landais, L., Camelin, J.-C., Calmels, T., Berrebi‐Bertrand, I., Lecomte, J., Parmentier, R., Anaclet, C., Lin, J., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111039 · Cited by 255
Self-citationThe histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders
Passani, M. B., Lin, J.-S., Hancock, A., Crochet, S., & Blandina, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.003 · Cited by 255
Lin, J. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.2000.0116 · Cited by 246
Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist
Ligneau, X., Lin, J.-S., Vanni-Mercier, G., Jouvet, M., Muir, J. L., Ganellin, C. R., Stark, H., Elz, S., Schunack, W., & Schwartz, J.-C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37840-1 · Cited by 242
Self-citationExcessive daytime sleepiness in parkinsonism
Arnulf, I. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.01.001 · Cited by 235
Lin, J.-S., Sakai, K., Vanni-Mercier, G., Arrang, J.-M., Garbarg, M., Schwartz, J.-C., & Jouvet, M. (1990) · Brain Research · doi:10.1016/0006-8993(90)91508-e · Cited by 223
Self-citationWatanabe, T., Taguchi, Y., Hayashi, H., Tanaka, J., Shiosaka, S., Tohyama, M., Kubota, H., Terano, Y., & Wada, H. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90308-7 · Cited by 214
Histamine as a transmitter in brain
Schwartz, J.-C. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90083-1 · Cited by 211
Self-citationHistamine H3 Receptor Antagonists Go to Clinics
Sander, K., Kottke, T., & Stark, H. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2163 · Cited by 193
Histaminergic Pathway in Rat Brain Evidenced by Lesions of the Medial Forebrain Bundle
Garbarg, M., Barbin, G., Féger, J., & Schwartz, J.-C. (1974) · Science · doi:10.1126/science.186.4166.833 · Cited by 183
Self-citationH1 and H2 receptors in the histamine-induced accumulation of cyclic AMP in guinea pig brain slices
BAUDRY, M., MARTRES, M.-P., & SCHWARTZ, J.-C. (1975) · Nature · doi:10.1038/253362a0 · Cited by 183
Self-citationNishino, S., Sakurai, E., Nevšímalová, S., Yoshida, Y., Watanabe, T., Yanai, K., & Mignot, E. J.-M. (2009) · SLEEP · doi:10.1093/sleep/32.2.175 · Cited by 172
Ligneau, X., Morisset‐Lopez, S., Tardivel‐Lacombe, J., Gbahou, F., Ganellin, C. R., Stark, H., Schunack, W. G., Schwartz, J., & Arrang, J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703712 · Cited by 147
Self-citationHistamine H3 receptor antagonists: From target identification to drug leads
Bonaventure, P., Letavic, M. A., Dugovic, C., Wilson, S. M. B., Aluisio, L. E., Pudiak, C. M., Lord, B., Mazur, C., Kamme, F., Nishino, S., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.031 · Cited by 134
Anichtchik, O. V., Peitsaro, N., Rinne, J. O., Kalimo, H., & Panula, P. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0413 · Cited by 118
Ligneau, X., Landais, L., Perrin, D., Piriou, J., Uguen, M., Denis, E., Robert, P., Parmentier, R., Anaclet, C., Lin, J., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.023 · Cited by 110
Self-citationHistamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases
Raddatz, R., Tao, M., & Hudkins, R. L. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411027 · Cited by 74
Perspectives on cognitive domains, H3receptor ligands and neurological disease
Hancock, A. A., & Fox, G. B. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.10.1237 · Cited by 66
Arrang, J. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78009-6 · Cited by 60
Croyal, M., Dauvilliers, Y. A., Labeeuw, O., Capet, M., Schwartz, J.-C., & Robert, P. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.09.045 · Cited by 54
Self-citationBRAIN HISTIDINE DECARBOXYLASE ACTIVITY IN PARKINSON'S DISEASE
Garbarg, M., Javoy-Agid, F., Schwartz, J. C., & Agid, Y. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91613-6 · Cited by 51
Self-citationLevoin, N., Calmels, T., Poupardin, O., Labeeuw, O., Danvy, D., Robert, P., Berrebi‐Bertrand, I., Ganellin, C. R., Schunack, W. G., Stark, H., et al. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800042 · Cited by 38
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
Panula, P., Chazot, P. L., Cowart, M., Gutzmer, R., Leurs, R., Liu, W. L. S., Stark, H., Thurmond, R. L., & Haas, H. L. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010249 · Cited by 575
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Thangam, E. B., Jemima, E. A., Singh, H., Baig, M. S., Khan, M., Mathias, C. B., Church, M. K., & Saluja, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01873 · Cited by 534
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial
Dauvilliers, Y., Bassetti, C., Lammers, G. J., Arnulf, I., Mayer, G., Rodenbeck, A., Lehert, P., Ding, C.-L., Lecomte, J.-M., & Schwartz, J.-C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70225-4 · Cited by 362
Self-citation
Metadata
- Authors
- Schwartz, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-05-26
- Volume
- 163
- Issue
- 4
- Pages
- 713-721
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2127398647
- Cited by
- 318
- References
- 38
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.